CN1216051C - 大环类似物及其使用和制备的方法 - Google Patents

大环类似物及其使用和制备的方法 Download PDF

Info

Publication number
CN1216051C
CN1216051C CN99809658XA CN99809658A CN1216051C CN 1216051 C CN1216051 C CN 1216051C CN 99809658X A CN99809658X A CN 99809658XA CN 99809658 A CN99809658 A CN 99809658A CN 1216051 C CN1216051 C CN 1216051C
Authority
CN
China
Prior art keywords
solution
etoac
mixture
add
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN99809658XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1312804A (zh
Inventor
B·A·利特菲尔德
M·帕尔梅
B·M·瑟勒特斯基
M·J·托勒
M·J·余
W·郑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1216051(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of CN1312804A publication Critical patent/CN1312804A/zh
Application granted granted Critical
Publication of CN1216051C publication Critical patent/CN1216051C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CN99809658XA 1998-06-17 1999-06-16 大环类似物及其使用和制备的方法 Expired - Lifetime CN1216051C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
US60/089682 1998-06-17

Publications (2)

Publication Number Publication Date
CN1312804A CN1312804A (zh) 2001-09-12
CN1216051C true CN1216051C (zh) 2005-08-24

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99809658XA Expired - Lifetime CN1216051C (zh) 1998-06-17 1999-06-16 大环类似物及其使用和制备的方法

Country Status (22)

Country Link
US (4) US6214865B1 (enExample)
EP (4) EP1087960B1 (enExample)
JP (1) JP4454151B2 (enExample)
KR (1) KR100798600B1 (enExample)
CN (1) CN1216051C (enExample)
AT (1) ATE502932T1 (enExample)
AU (1) AU762998B2 (enExample)
BE (1) BE2011C028I2 (enExample)
BR (1) BRPI9911326B8 (enExample)
CA (3) CA2335300C (enExample)
CY (2) CY1111516T1 (enExample)
DE (2) DE122011100031I1 (enExample)
DK (1) DK1087960T3 (enExample)
FR (1) FR11C0038I2 (enExample)
HU (1) HU227912B1 (enExample)
IL (1) IL139960A0 (enExample)
LU (1) LU91854I2 (enExample)
NO (5) NO328280B1 (enExample)
NZ (1) NZ508597A (enExample)
PT (1) PT1087960E (enExample)
WO (1) WO1999065894A1 (enExample)
ZA (1) ZA200007159B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697655B2 (en) 2021-06-08 2023-07-11 Wisdom Pharmaceutical Co., Ltd Synthesis of eribulin mesylate

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
AU2003228354B8 (en) 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
CA2526385C (en) * 2003-05-29 2008-07-22 Abbott Laboratories Continuous dosing regimen with abt-751
US20070196418A1 (en) * 2003-07-29 2007-08-23 Michael Lewis Drug delivery methods and devices
PL2522663T3 (pl) * 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
CN1993342A (zh) * 2004-06-03 2007-07-04 卫材株式会社 用于制备软海绵素b的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) * 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
EP2578576B9 (en) 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
US8598373B2 (en) * 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
US8765974B2 (en) * 2009-04-14 2014-07-01 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2012344697A1 (en) 2011-11-30 2014-07-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
IN2014MN01521A (enExample) * 2011-12-29 2015-05-01 Alphora Res Inc
WO2013142999A1 (en) * 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
RU2689977C2 (ru) 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP6511613B2 (ja) * 2013-07-03 2019-05-15 サンド・アクチエンゲゼルシヤフト ハリコンドリンＢの大環状Ｃ１−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−ＳＯ２−（ｐ−トリル）基を含有する中間体
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
HUE049387T2 (hu) 2013-11-04 2020-09-28 Eisai R&D Man Co Ltd A halichondrin B analógjainak szintézisében hasznos makrociklizációs reakciók és köztitermékek
SG11201604545XA (en) 2013-12-06 2016-07-28 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) * 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
KR20170039096A (ko) * 2014-05-28 2017-04-10 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료에 있어서 에리불린의 용도
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
WO2016182850A1 (en) 2015-05-08 2016-11-17 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
JP6786610B2 (ja) * 2016-02-12 2020-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンの合成における中間体および関連する合成方法
EP3449921B1 (en) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin for inhibiting tumor growth
BR112018074287A2 (pt) 2016-05-26 2019-06-18 Dr Reddys Laboratories Ltd processo para preparação de eribulina e intermediários da mesma
MX390072B (es) 2016-06-30 2025-03-20 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2018071792A1 (en) 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
JP2020511404A (ja) * 2016-11-23 2020-04-16 ドクター レディズ ラボラトリーズ リミテッド エリブリン及びその中間体の調製方法
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
ES2932832T3 (es) 2017-01-02 2023-01-26 Yonsung Fine Chemical Co Ltd Intermedio de producción de mesilato de eribulina, y método para producir el mismo
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
HRP20221385T1 (hr) 2017-04-05 2023-01-06 President And Fellows Of Harvard College Makrociklički spoj i njegova uporaba
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
KR102177992B1 (ko) * 2017-11-09 2020-11-12 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en) 2017-11-21 2019-05-31 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
KR102799793B1 (ko) 2018-01-03 2025-04-25 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN112437775A (zh) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 用于制备艾日布林及其中间体的纯化方法
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US20220089607A1 (en) * 2018-11-28 2022-03-24 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
CA3124412A1 (en) 2018-12-20 2020-06-25 Auransa Inc. Analogues of pentamidine and uses therefor
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
PH12022551036A1 (en) 2019-11-07 2023-05-29 Eisai R&D Man Co Ltd Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
WO2021148003A1 (zh) * 2020-01-22 2021-07-29 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
EP4374879A1 (en) * 2021-07-22 2024-05-29 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
TW202434308A (zh) * 2023-01-17 2024-09-01 大陸商成都百利多特生物藥業有限責任公司 一種艾日布林類藥物的偶聯物
CN118834221B (zh) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 一种软海绵素b类似物
TW202518024A (zh) 2023-10-13 2025-05-01 日商衛材R&D企管股份有限公司 抗體－藥物軛合物代謝物
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (zh) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 艾日布林衍生物及其抗体药物偶联物和医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
IL139960A0 (en) * 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
PL2522663T3 (pl) * 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
EP2578576B9 (en) * 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US8598373B2 (en) * 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
SG182612A1 (en) * 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11697655B2 (en) 2021-06-08 2023-07-11 Wisdom Pharmaceutical Co., Ltd Synthesis of eribulin mesylate

Also Published As

Publication number Publication date
HK1035534A1 (en) 2001-11-30
NO328280B1 (no) 2010-01-25
BRPI9911326B8 (pt) 2021-05-25
CY1111516T1 (el) 2014-04-09
AU762998B2 (en) 2003-07-10
EP2277873A1 (en) 2011-01-26
CA2632433C (en) 2012-02-07
IL139960A0 (en) 2002-02-10
NO20093217L (no) 2001-02-15
NO20006316L (no) 2001-02-15
RU2245335C2 (ru) 2005-01-27
HUP0103357A2 (hu) 2002-01-28
NO20006316D0 (no) 2000-12-12
CA2755266C (en) 2014-08-12
EP1087960A1 (en) 2001-04-04
NO2022019I1 (no) 2022-06-03
EP2272840B1 (en) 2012-08-22
HUP0103357A3 (en) 2002-10-28
US6469182B1 (en) 2002-10-22
FR11C0038I2 (fr) 2013-01-11
DE122011100031I1 (de) 2011-12-15
BR9911326B1 (pt) 2015-01-06
FR11C0038I1 (fr) 2011-10-14
JP4454151B2 (ja) 2010-04-21
NO2011026I1 (no) 2012-01-09
DK1087960T3 (da) 2011-06-14
CY2011010I1 (el) 2014-04-09
AU762998C (en) 2000-01-05
CA2632433A1 (en) 1999-12-23
NZ508597A (en) 2004-01-30
US8148554B2 (en) 2012-04-03
EP1087960B1 (en) 2011-03-23
WO1999065894A1 (en) 1999-12-23
CA2755266A1 (en) 1999-12-23
AU4573999A (en) 2000-01-05
ATE502932T1 (de) 2011-04-15
EP1087960A4 (en) 2004-12-01
US6365759B1 (en) 2002-04-02
DE69943296D1 (de) 2011-05-05
KR20010083050A (ko) 2001-08-31
CA2335300C (en) 2008-10-07
US20110172446A1 (en) 2011-07-14
PT1087960E (pt) 2011-06-17
EP2272839B1 (en) 2012-08-22
EP2277873B1 (en) 2012-05-30
US6214865B1 (en) 2001-04-10
EP2272839A1 (en) 2011-01-12
NO2011026I2 (no) 2012-06-11
HU227912B1 (en) 2012-05-29
NO331183B1 (no) 2011-10-24
BE2011C028I2 (en) 2018-08-24
EP2272840A1 (en) 2011-01-12
JP2002518384A (ja) 2002-06-25
CN1312804A (zh) 2001-09-12
KR100798600B1 (ko) 2008-01-28
CA2335300A1 (en) 1999-12-23
ZA200007159B (en) 2001-12-04
LU91854I2 (fr) 2011-10-17
CY2011010I2 (el) 2014-04-09
BR9911326A (pt) 2001-04-03
NO2011018I1 (no) 2011-09-26

Similar Documents

Publication Publication Date Title
CN1216051C (zh) 大环类似物及其使用和制备的方法
CN1209360C (zh) 16－卤－依泊昔酮衍生物、其制备方法及其医药用途
CN1349534A (zh) 6－链烯基－、6－链炔基－和6－环氧－epothilone衍生物,它们的制备方法和它们在药物制剂中的用途
CN1151127C (zh) 吲哚衍生物及其用于治疗恶性肿瘤和其它基于病理细胞增生的疾病的用途
CN1055089C (zh) 蛋白激酶c抑制剂的中间体及其制法
CN1097044C (zh) 紫杉烷衍生物以及含有该衍生物的药物
CN1153771C (zh) 苯并呋喃并[3，4-f]喹啉衍生物、含有其的药物组合物及其应用
CN1215051A (zh) α－取代苯基丙酸衍生物及含这种化合物的药品
CN1175574A (zh) 环烷吡啶
CN1246862A (zh) 环氧噻酮类似物
CN1759115A (zh) 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
CN1211244A (zh) 根赤壳菌素衍生物
CN1067053C (zh) 单环β－内酰胺类抗生素衍生物的中间体的制备方法
CN1812986A (zh) 呋咱并苯并咪唑类化合物
CN1217719A (zh) 新型苯并呋喃酮衍生物及其制备方法
CN1226893A (zh) 精选的K－252a衍生物
CN1085901A (zh) 制备含咪唑并哒嗪衍生物的抗肿瘤药物组合物的方法
CN1157394C (zh) 二氢呋喃并[3,4-b]喹啉-1-酮类化合物、其制备方法和含有这些化合物的药物组合物
CN1993342A (zh) 用于制备软海绵素b的中间体
CN1249057C (zh) 用作抗菌剂的色烯基甲基嘧啶二胺
CN1138040A (zh) 新的环己烷化合物，其制备方法和含有它们的药物组合物
CN1034498C (zh) 用于抑制胆固醇生物合成的八氢萘肟衍生物，其制备方法和用途
CN100338066C (zh) 六环化合物
CN1942434A (zh) 茚衍生物及其制备方法
CN1028993C (zh) 生产新的核酸衍生物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: WEI CAI & D MANAGEMENT CO., LTD.

Free format text: FORMER OWNER: EISAI CO., LTD.

Effective date: 20080321

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080321

Address after: Tokyo, Japan, Japan

Patentee after: Eisai R. & D. Man Co., Ltd.

Address before: Tokyo, Japan

Patentee before: Eisai co., Ltd.

CX01 Expiry of patent term

Granted publication date: 20050824

CX01 Expiry of patent term